- Home
- XAIR vs CTXR Comparison
XAIR vs CTXR Comparison
Compare XAIR & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- CTXR
- Stock Information
- Founded
- XAIR 2011
- CTXR 2007
- Country
- XAIR United States
- CTXR United States
- Employees
- XAIR N/A
- CTXR N/A
- Industry
- XAIR Medical/Dental Instruments
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- XAIR Health Care
- CTXR Health Care
- Exchange
- XAIR Nasdaq
- CTXR Nasdaq
- Market Cap
- XAIR 17.0M
- CTXR 18.7M
- IPO Year
- XAIR N/A
- CTXR N/A
- Fundamental
- Price
- XAIR $2.25
- CTXR $1.35
- Analyst Decision
- XAIR Strong Buy
- CTXR Strong Buy
- Analyst Count
- XAIR 1
- CTXR 3
- Target Price
- XAIR $11.00
- CTXR $53.00
- AVG Volume (30 Days)
- XAIR 190.1K
- CTXR 360.0K
- Earning Date
- XAIR 08-12-2025
- CTXR 08-12-2025
- Dividend Yield
- XAIR N/A
- CTXR N/A
- EPS Growth
- XAIR N/A
- CTXR N/A
- EPS
- XAIR N/A
- CTXR N/A
- Revenue
- XAIR $4,782,000.00
- CTXR N/A
- Revenue This Year
- XAIR $266.61
- CTXR N/A
- Revenue Next Year
- XAIR $140.76
- CTXR $851.67
- P/E Ratio
- XAIR N/A
- CTXR N/A
- Revenue Growth
- XAIR 168.20
- CTXR N/A
- 52 Week Low
- XAIR $2.02
- CTXR $0.65
- 52 Week High
- XAIR $13.52
- CTXR $17.00
- Technical
- Relative Strength Index (RSI)
- XAIR 35.48
- CTXR 49.89
- Support Level
- XAIR $2.02
- CTXR $1.18
- Resistance Level
- XAIR $2.42
- CTXR $1.45
- Average True Range (ATR)
- XAIR 0.20
- CTXR 0.10
- MACD
- XAIR -0.04
- CTXR -0.00
- Stochastic Oscillator
- XAIR 17.97
- CTXR 62.96
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.